*Chlamydia: The Female Reproductive System and Infertility DOI: http://dx.doi.org/10.5772/intechopen.111756*

Variants in toll-like receptor 1 and 4 genes are associated with chlamydia trachomatis among women with pelvic inflammatory disease. The Journal of Infectious Diseases. 2012;**205**(4):603-609

[29] Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. The New England Journal of Medicine. 1996;**334**(21):1362-1366

[30] Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of Central Sweden. Sexually Transmitted Diseases. 1996;**23**(5):384-391

[31] Quinn TC, Gaydos C, Shepherd M, Bobo L, Hook EW 3rd, Viscidi R, et al. Epidemiologic and microbiologic correlates of chlamydia trachomatis infection in sexual partnerships. Journal of the American Medical Association. 1996;**276**(21):1737-1742

[32] Lesiak-Markowicz I, Schötta A-M, Stockinger H, Stanek G, Markowicz M. Chlamydia trachomatis serovars in urogenital and ocular samples collected 2014-2017 from Austrian patients. Scientific Reports. 2019;**9**:18327

[33] Morré SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader PC, Schirm J, et al. Urogenital chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: An association with clinical manifestations? Journal of Clinical Microbiology. 2000;**38**:2292-2296

[34] Chen Y, Chen J, Yang L, Jiang Y, Li L, Yi W, et al. Distribution of chlamydia trachomatis genotypes in infective diseases of the female lower genital tract. Medical Science Monitor. 2017;**23**:4477-4481

[35] Abdelsamed H, Peters J, Byrne GI. Genetic variation in chlamydia trachomatis and their hosts: Impact on disease severity and tissue tropism. Future Microbiology. 2013;**8**:1129-1146

[36] Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key molecular events in cervical cancer development. Medicina. 2019;**55**:384

[37] Sylvan SPE, Von Krogh G, Tiveljung A, Siwerth B-M, Henriksson L, Norén L, et al. Screening and genotyping of genital chlamydia trachomatis in urine specimens from male and female clients of youth-health centers in Stockholm County. Sexually Transmitted Diseases. 2002;**29**:379-386

[38] Sabbatucci M, Salfa MC, Regine V, Pezzotti P, Suligoi B. Estimated burden of chlamydia trachomatis female infection and consequent severe pelvic inflammatory disease, Italy, 2005-2016. Annali dell'Istituto Superiore di Sanità. 2019;**55**:217-223

[39] Borrego MJ, Gomes JP, Lefebvre JF, Eb F, Orfila J, Catry MA. Genotyping of Portuguese chlamydia trachomatis urogenital isolates. Sexually Transmitted Infections. 1997;**73**:561-563

[40] Casillas-Vega N, Morfín-Otero R, García S, Llaca-Díaz J, Rodríguez-Noriega E, Camacho-Ortiz A, et al. Frequency and genotypes of chlamydia trachomatis in patients attending the obstetrics and gynecology clinics in Jalisco, Mexico and correlation with sociodemographic, behavioral, and biological factors. BMC Women's Health. 2017;**17**:83

[41] Baud D, Goy G, Jaton K, Osterheld MC, Blumer S, Borel N, et al. Role of chlamydia trachomatis in miscarriage. Emerging Infectious Diseases. 2011;**17**(9):1630-1635

[42] Rours GI, Duijts L, Moll HA, Arends LR, de Groot R, Jaddoe VW, et al. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: A population-based prospective cohort study. European Journal of Epidemiology. 2011;**26**(6):493-502

[43] Paavonen J, Karunakaran KP, Noguchi Y, Anttila T, Bloigu A, Dillner J, et al. Serum antibody response to the heat shock protein 60 of chlamydia trachomatis in women with developing cervical cancer. American Journal of Obstetrics and Gynecology. 2003;**189**:1287-1292

[44] Zhu H, Shen Z, Luo H, Zhang W, Zhu X. Chlamydia trachomatis infectionassociated risk of cervical cancer: A meta analysis. Medicine. 2016;**95**:e3077

[45] Yang X, Siddique A, Khan AA, Wang Q, Malik A, Jan AT, et al. Chlamydia trachomatis infection: Their potential implication in the etiology of cervical cancer. Journal of Cancer. 2021;**12**:4891-4900

[46] Prozialeck WC, Fay MJ, Lamar PC, Pearson CA, Sigar I, Ramsey KH. Chlamydia trachomatis disrupts N-cadherin-dependent cell-cell junctions and sequesters beta-catenin in human cervical epithelial cells. Infection and Immunity. 2002;**70**:2605-2613

[47] Jensen KE, Thomsen LT, Schmiedel S, Frederiksen K, Norrild B, van den Brule A, et al. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: A cohort study. Sexually Transmitted Infections. 2014;**90**:550-555

[48] Simonetti AC, Melo JH, de Souza PR, Bruneska D, de Lima Filho JL. Immunological's host profile for HPV and chlamydia trachomatis, a cervical cancer cofactor. Microbes and Infection. 2009;**11**:435-442

[49] Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikäheimo I, et al. Serotypes of chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA. 2001;**285**:47-51

[50] Xie X, Yang M, Ding Y, Chen J. Microbial infection, inflammation and epithelial ovarian cancer. Oncology Letters. 2017;**14**:1911-1919

[51] Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K. Viral and bacterial aetiologies of epithelial ovarian cancer. European Journal of Clinical Microbiology & Infectious Diseases. 2012;**31**:2311-2317

[52] Bodzek P, Partyka R, Damasiewicz-Bodzek A. Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer. Journal of Ovarian Research. 2014;**7**:30

[53] Hosseininasab-nodoushan S-A, Ghazvini K, Jamialahmadi T, Keikha M, Sahebkar A. Association of chlamydia and mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis. Semin. Cancer Biol. 2021;**86** (Pt 2):923-928

[54] Peters RPH, Nijsten N, Mutsaers J, Jansen CL, Morré SA, van Leeuwen AP. Screening of oropharynx and Anorectum increases prevalence of chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sexually Transmitted Diseases. 2011;**38**(9):783-787

*Chlamydia: The Female Reproductive System and Infertility DOI: http://dx.doi.org/10.5772/intechopen.111756*

[55] Centers for Disease Control and Prevention. Chlamydial Infections. CDC

[56] Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR - Recommendations and Reports. 2014;**63**(RR-02):1-19

[57] Knox J, Tabrizi SN, Miller P, Petoumenos K, Law M, Chen S, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of chlamydia trachomatis, Neisseria gonorrhoeae, and trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sexually Transmitted Diseases. 2002;**29**(11):647-654

[58] Masek BJ, Arora N, Quinn N, Aumakhan B, Holden J, Hardick A, et al. Performance of three nucleic acid amplification tests for detection of chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an internet-based screening program. Journal of Clinical Microbiology. 2009;**47**(6):1663-1667

[59] Sarıer M, Demir M, Turgut H, Hizel A, Emek M, Kukul E, et al. New approach to microscopy of gramstained urethral smear: The kissing slide method. Sexually Transmitted Diseases. 2020;**47**(10):712-715

[60] Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR - Recommendations and Reports. 2015;**64**(RR-03):1-137

[61] Harkins AL, Munson E. Molecular diagnosis of sexually transmitted chlamydia trachomatis in the United

States. ISRN Obstetrics and Gynecology. 2011;**2011**:279149

[62] Gaydos CA, Ferrero DV, Papp J. Laboratory aspects of screening men for chlamydia trachomatis in the new millennium. Sexually Transmitted Diseases. 2008;**35**(Suppl. 11):S45-S50

[63] Chernesky M, Freund GG, Hook E 3rd, Leone P, D'Ascoli P, Martens M. Detection of chlamydia trachomatis and Neisseria gonorrhoeae infections in north American women by testing SurePath liquid-based pap specimens in APTIMA assays. Journal of Clinical Microbiology. 2007;**45**(8):2434-2438

[64] Schillinger JA, Katz BP, Markowitz LE, Braslins PG, Shrier LA, Madico G, et al. Genotype-specific concordance of chlamydia trachomatis genital infection within heterosexual partnerships. Sexually Transmitted Diseases. 2016;**43**:741-749

[65] Sarıer M. Prevalance of Polymicrobial infection in urethritis. Journal of Urological Surgery. 2019;**6**(3):180-183

[66] Sarıer M, Duman İ, Göktaş Ş, Demir M, Kukul E. Results of multiplex polymerase chain reaction assay to identify urethritis pathogens. Journal of Urological Surgery. 2017;**1**:18-22

[67] Hadgu A, Sternberg M. Reproducibility and specificity concerns associated with nucleic acid amplification tests for detecting chlamydia trachomatis. European Journal of Clinical Microbiology & Infectious Diseases. 2009;**28**(1):9-15

[68] Dukers-Muijrers NH, Morré SA, Speksnijder A, van der Sande MA, Hoebe CJ. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One. 2012;**7**(3):e34108

[69] Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-care testing for sexually transmitted infections: A review of recent developments. Archives of Pathology & Laboratory Medicine. 2020;**144**:1344-1351

[70] Harding-Esch EM, Fuller SS, Chow SC, Nori AV, Harrison MA, Parker M, et al. Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: A multicentre cross-sectional preclinical evaluation. Clinical Microbiology and Infection. 2019;**25**(380):e1-380.e7

[71] Sheringham J, Baraitser P, Simms I, Hart G, Raine R. Chlamydia screening in England: A qualitative study of the narrative behind the policy. BMC Public Health. 2012;**12**:317

[72] Low N, Hocking JS, van Bergen J. The changing landscape of chlamydia control strategies. Lancet. 2021;**398**:1386-1388

[73] Kretzschmar M, Welte R, van den Hoek A, Postma MJ. Comparative modelbased analysis of screening programs for chlamydia trachomatis infections. American Journal of Epidemiology. 2001;**153**:90-101

[74] van Aar F, de Moraes M, Morré SA, van Bergen JE, van der Klis FR, Land JA, et al. Chlamydia trachomatis IgG seroprevalence in the general population of the Netherlands in 1996 and in 2007: Differential changes by gender and age. Sexually Transmitted Infections. 2014;**90**:434-440

[75] Chernesky M, Jang D, Martin I, Arias M, Shah A, Smieja M, et al. Mycoplasma genitalium, chlamydia trachomatis, and Neisseria gonorrhoeae detected with aptima assays performed on self-obtained vaginal swabs and urine collected at home and in a clinic. Sexually Transmitted Diseases. 2019;**46**:e87-e89

[76] Graseck AS, Shih SL, Peipert JF. Home versus clinic-based specimen collection for chlamydia trachomatis and Neisseria gonorrhoeae. Expert Review of Anti-Infective Therapy. 2011;**9**:183-194

[77] Hoenderboom BM, van Ess EF, van den Broek IVF, van Loo IHM, Hoebe C, Ouburg S, et al. Chlamydia trachomatis antibody detection in home-collected blood samples for use in epidemiological studies. Journal of Microbiological Methods. 2018;**144**:164-167

[78] Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, et al. Repeated chlamydia trachomatis genital infections in adolescent women. The Journal of Infectious Diseases. 2010;**201**:42-51

[79] Ditkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost-benefit analysis of chlamydia trachomatis screening in pregnant women in a high burden setting in the United States. BMC Infectious Diseases. 2017;**17**:155

[80] LaMontagne DS, Fenton KA, Randall S, Anderson S, Carter P. Establishing the National Chlamydia Screening Programme in England: Results from the first full year of screening. Sexually Transmitted Infections. 2004;**80**:335-341

[81] Yuguero O, Fernández-Armenteros JM, Vilela Á, Aramburu J, Laín R, Godoy P. Preliminary results of a screening Programme for chlamydia in an asymptomatic young population in Spain. Frontiers in Public Health. 2021;**9**:615110

[82] Low N, Cassell JA, Spencer B, Bender N, Martin Hilber A, van Bergen J, et al. Chlamydia control activities in Europe: Cross-sectional survey. European Journal of Public Health. 2011;**22**:556-561

*Chlamydia: The Female Reproductive System and Infertility DOI: http://dx.doi.org/10.5772/intechopen.111756*

[83] Cha S, Newman DR, Rahman M, Peterman TA. High rates of repeat chlamydial infections among young women-Louisiana, 2000-2015. Sexually Transmitted Diseases. 2019;**46**:52-57

[84] Söderqvist J, Gullsby K, Stark L, Wikman M, Karlsson R, Herrmann B. Internet-based self-sampling for chlamydia trachomatis testing: A national evaluation in Sweden. Sexually Transmitted Infections. 2020;**96**:160-165

[85] Huai P, Li F, Chu T, Liu D, Liu J, Zhang F. Prevalence of genital chlamydia trachomatis infection in the general population: A meta-analysis. BMC Infectious Diseases. 2020;**20**:589

[86] ML LF, U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. preventive services task force recommendation statement. Annals of Internal Medicine. 2014;**161**(12):902-910

[87] National Guideline Clearinghouse. Screening for Chlamydial Infection: Recommendation Statement. National Guideline Clearinghouse

[88] Kohlhoff SA, Hammerschlag MR. Treatment of chlamydial infections: 2014 update. Expert Opinion on Pharmacotherapy. 2015;**16**(2):205-212

[89] Huemer M, Shambat SM, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence—Implications for human health and treatment perspectives. EMBO Reports. 2020;**21**:e51034

[90] Ljubin-Sternak S, Mestrovic T, Vilibic-Cavlek T, Mlinaric-Galinovic G, Sviben M, Markotic A, et al. In vitro susceptibility of urogenital chlamydia trachomatis strains in a country with high azithromycin consumption rate. Folia Microbiologica. 2013;**58**:361-365

[91] Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal chlamydia trachomatis in men and women? Sexually Transmitted Infections. 2012;**88**:352

[92] Manavi K, Hettiarachchi N, Hodson J. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. International Journal of STD & AIDS. 2016;**27**:1303-1308

[93] Wyrick PB, Knight ST. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders chlamydia trachomatis refractory to azithromycin. The Journal of Antimicrobial Chemotherapy. 2004;**54**:79-85

[94] Shima K, Ledig S, Loeper N, Schiefer A, Pfarr K, Hoerauf A, et al. Effective inhibition of rifampicinresistant chlamydia trachomatis by the novel DNA-dependent RNA polymerase inhibitor corallopyronin a. International Journal of Antimicrobial Agents. 2018;**52**:523-524

[95] Loeper N, Graspeuntner S, Ledig S, Kaufhold I, Hoellen F, Schiefer A, et al. Elaborations on Corallopyronin a as a novel treatment strategy against genital chlamydial infections. Frontiers in Microbiology. 2019;**10**:943

[96] Yang S, Traore Y, Jimenez C, Ho EA. Autophagy induction and PDGFR-β knockdown by siRNA-encapsulated nanoparticles reduce chlamydia trachomatis infection. Scientific Reports. 2019;**9**:1306

[97] Núñez-Otero C, Bahnan W, Vielfort K, Silver J, Singh P, Elbir H, et al. A 2-Pyridone amide inhibitor of transcriptional activity in chlamydia trachomatis. Antimicrobial Agents and Chemotherapy. 2021;**65**:e01826-e01820

[98] Hamarsheh O, Amro A, Al-Zeer M. In vitro antibacterial activity of selected Palestinian medicinal plants against chlamydia trachomatis. Microbiological Research. 2021;**12**:656-662

[99] Lam HN, Lau T, Lentz A, Sherry J, Cabrera-Cortez A, Hug K, et al. Developing cyclic Peptomers as broad-Spectrum type III secretion system inhibitors in gram-negative bacteria. Antimicrobial Agents and Chemotherapy. 2021;**65**:e01690-e01620

[100] Itoh R, Kurihara Y, Yoshimura M, Hiromatsu K. Bortezomib eliminates persistent chlamydia trachomatis infection through rapid and specific host cell apoptosis. International Journal of Molecular Sciences. 2022;**23**:7434

[101] Barclay L. ACOG recommends expedited partner therapy for STIs. Medscape Medical News. WebMD Inc. May. 2015;**22**:1526-1528

[102] American College of Obstetricians and Gynecologists. Committee opinion no 632: Expedited partner therapy in the management of gonorrhea and chlamydial infection. Obstetrics and Gynecology. 2015;**125**(6):1526-1528

[103] World Health Organization. WHO Guidelines for the Treatment of Chlamydia Trachomatis. Geneva, Switzerland: World Health Organization; 2016

[104] Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. American Journal of Obstetrics and Gynecology. 2017;**216**(1):1-9

[105] Linhares IM, Witkin SS. Immunopathogenic consequences of chlamydia trachomatis 60 kDa heat shock protein expression in the female reproductive tract. Cell Stress & Chaperones. 2010;**15**(5):467-473

[106] Meikle S, Zhang X, Marine W, Calonge B, Hamman R, Betz G. Chlamydia trachomatis antibody titers and hysterosalpingography in predicting tubal disease in infertility patients. Fertility and Sterility. 1994;**62**(2):305-312

[107] Coppus S, Land J, Opmeer B, Steures P, Eijkemans M, Hompes P, et al. Chlamydia trachomatis IgG seropositivity is associated with lower natural conception rates in ovulatory subfertile women without visible tubal pathology. Human Reproduction. 2011;**26**(11):3061-3067

[108] Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, et al. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility and Sterility. 2015;**104**(6):1522-1526

[109] Stephens AJ, Aubuchon M, Schust DJ. Antichlamydial antibodies, human fertility, and pregnancy wastage. Infectious Diseases in Obstetrics and Gynecology. 2011;**2011**:525182

[110] Passos LG, Terraciano P, et al. The correlation between chlamydia trachomatis and female infertility: A systematic review. Revista Brasileira de Ginecologia e Obstetrícia. 2022;**44**(6):614-620

[111] Menon S, Stansfield SH, Logan B, Hocking JS, Timms P, Rombauts L, et al. Development and evaluation of a multiantigen peptide ELISA for the diagnosis of chlamydia trachomatis-related infertility in women. Journal of Medical Microbiology. 2016;**65**(09):915-922

[112] den Heijer CDJ, Hoebe CJPA, Driessen JHM, Wolffs P, van den Broek IVF, Hoenderboom BM, et al. *Chlamydia: The Female Reproductive System and Infertility DOI: http://dx.doi.org/10.5772/intechopen.111756*

Chlamydia trachomatis and the risk of pelvic inflammatory disease, ectopic pregnancy, and female infertility: A retrospective cohort study among primary care patients. Clinical Infectious Diseases. 2019;**69**(09):1517-1525

[113] Davies B, Turner KME, Frølund M, Ward H, May MT, Rasmussen S. Et al; Danish chlamydia study group. Risk of reproductive complications following chlamydia testing: A population-based retrospective cohort study in Denmark. The Lancet Infectious Diseases. 2016;**16**(09):1057-1064

[114] Ramadhani MY, Mirambo MM, Mbena H, Kihunrwa A, Mshana SE. High prevalence of chlamydia trachomatis infection among infertile women in Mwanza city, Tanzania: A need to introduce screening and treatment programme. Sexually Transmitted Infections. 2017;**93**(2):111

[115] Kayiira A, Zaake D, Lwetabe MW, Sekweyama P. Impact of genital chlamydia trachomatis infection on reproductive outcomes among infertile women undergoing tubal flushing: A retrospective cohort at a fertility Centre in Uganda. Fertility Research and Practice. 2019;**5**:16

[116] Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, et al. Diversity of vaginal microbiome and metabolome during genital infections. Scientific Reports. 2019;**9**(1):14095

[117] Parolin C, Foschi C, Laghi L, Zhu C, Banzola N, Gaspari V, et al. Insights intovaginal bacterial communities andmetabolicprofiles of chlamydia trachomatis infection: Positioning between eubiosis and dysbiosis. Frontiers in Microbiology. 2018;**9**:600

[118] Gazvani R, Coyne L, Anttila T, Saikku P, Paavonen J, Templeton A.

Antibodies to chlamydia trachomatis in serum and peritoneal fluid of women with endometriosis. Human Fertility (Cambridge, England). 2011;**14**(01):64-67

Section 5
